New Jersey headquartered Zoetis Inc.'s shares gained 0.80%, closing Tuesday's trading session at $50.22. The stock recorded a trading volume of 2.57 million shares. Shares of the Company have advanced 0.56% in the last month and 5.68% on an YTD basis. The stock is trading 4.39% above its 200-day moving average. Additionally, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 51.54.
On December 06th, 2016, Zoetis announced that its Board of Directors has authorized a $1.5 billion multi-year share repurchase program as part of its long-term capital allocation plans. The company's previous $500 million share repurchase program, which was approved in November 2014, is expected to be completed at the end of this year. The Board of Directors also declared a Q1 2017 dividend of $0.105 per share, an increase of 10.5% from the quarterly dividend rate paid in 2016. The dividend is to be paid on March 01st, 2017, to holders of record of the company's common stock on January 20th, 2017. See our free and comprehensive research report on ZTS at:
On Tuesday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. recorded a trading volume of 520,954 shares. The stock rose 1.95%, ending the day at $2.62. The Company's shares are trading below their 200-day moving average by 2.52%. Furthermore, shares of Rigel Pharma, which engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 38.45.
On November 01st, 2016, Rigel reported a net loss of $22.6 million, or $0.24 per basic and diluted share, for Q3 2016 compared to a net loss of $6.7 million, or $0.08 per basic and diluted share in Q3 2015. Contract revenues from collaborations of $3.8 million in Q3 2016 represented the remaining amortization of the $30.0 million upfront payment pursuant to Rigel's collaboration and license agreement with Bristol-Myers Squibb. As of September 30th, 2016, Rigel had cash, cash equivalents, and short-term investments of $85.3 million, compared to $126.3 million as of December 31st, 2015. RIGL free research report PDF is just a click away at:
Chesterfield, the UK-based Mallinckrodt PLC's stock finished the day 0.30% higher at $53.72 with a total trading volume of 1.35 million shares. Shares of the Company, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, the Middle East, Africa, and internationally, are trading below their 50-day moving average by 14.05%. The stock has an RSI of 37.61.
On November 29th, 2016, Mallinckrodt reported that net sales were $887.2 million in Q4 FY16, up 13.9% from Q4 FY15. The company's GAAP gross profit was $490.2 million in Q4 FY16, up 15.1% on a y-o-y basis. Diluted GAAP earnings per share from continuing operations for Q4 FY16 was $1.01 compared to $0.62 per diluted share in Q4 FY15.
On November 30th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $87 a share to $85 a share. Sign up for your complimentary report on MNK at:
Shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. ended yesterday's session 2.43% lower at $14.05. The stock recorded a trading volume of 997,019 shares. The Company's shares have advanced 12.40% in the last one month. The stock is trading 34.83% below its 50-day moving average. Moreover, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 28.38.
On November 23rd, 2016, research firm Credit Suisse downgraded the Company's stock rating from 'Neutral' to 'Underperform'.
On December 01st, 2016, Diplomat Pharmacy announced that it will be dispensing DARZALEX® (daratumumab) in combination with REVLIMID® (lenalidomide) and dexamethasone or with VELCADE® (bortezomib) and dexamethasone. DARZALEX was recently approved by the Food and Drug Administration to treat patients with multiple myeloma who have received at least one other treatment. Register for free on Stock-Callers.com and download the latest research report on DPLO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA